<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:myov="http://myovant.com/20200801" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_456ee20e090e448db7c36555544e02d4" contextRef="c20200801to20200801" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_800b32d3f7cb48f0934841a2a32c4fbf" contextRef="c20200801to20200801">0001679082</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="myov-20200801.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20200801to20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 14pt;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">UNITED STATES</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 14pt;">
        <div><br />
        </div>

      </div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_12725b09337043f7b1399820590ad521" contextRef="c20200801to20200801">8-K</ix:nonNumeric></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_7a84d5f00930441ea68731763497a7a6" contextRef="c20200801to20200801" format="ixt:datemonthdayyearen">August 1, 2020</ix:nonNumeric></span></div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 24pt;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_82fbc02000b4437cb9b6fa27b5fddec6" contextRef="c20200801to20200801">Myovant Sciences Ltd.</ix:nonNumeric><br />
        </div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4fdd52b7bc4f4d629393017cf2a54a72">


  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_f41e8a7b63f941c5b08729abe9aed821" contextRef="c20200801to20200801" format="ixt-sec:edgarprovcountryen">Bermuda</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_02097b2626344455b0fc9098225a8334" contextRef="c20200801to20200801">001-37929</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_387d0de114f9455bb1c15f4e225077e5" contextRef="c20200801to20200801">98-1343578</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or other jurisdiction of incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Commission File No.)</div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z200077e3bb744a258707eb6a35a9f98a">


  <tr>

    <td style="width: 48.85%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_221abf6a0409410a9fee0177d705b63e" contextRef="c20200801to20200801">Suite 1, 3rd Floor</ix:nonNumeric><br />
              </div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_fbbd3bb2e482443bad87a036fd21d1dc" contextRef="c20200801to20200801">11-12 St. James&#8217;s Square</ix:nonNumeric><br />
              </div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_18f586dd06e04689ba0a6a96f88c5d55" contextRef="c20200801to20200801">London</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_33bd4ec3627642efa9ad9ae69927c351" contextRef="c20200801to20200801">SW1Y 4LB</ix:nonNumeric></div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_4059380a271b4ec287047c19e69b1c81" contextRef="c20200801to20200801" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49.16%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Not Applicable</div>
            </td>

  </tr>

  <tr>

    <td style="width: 48.85%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Address of principal executive office)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49.16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: center; color: rgb(0, 0, 0);">Registrant&#8217;s telephone number, including area code:&#160; <span style="font-weight: bold;">+<ix:nonNumeric name="dei:CountryRegion" id="Fact_a19b0d477fb4464d86362b28f081e715" contextRef="c20200801to20200801">44</ix:nonNumeric>
            <ix:nonNumeric name="dei:CityAreaCode" id="Fact_99c6e8bff6824801ab9a7608b0be242d" contextRef="c20200801to20200801">207</ix:nonNumeric></span> <span style="font-weight: bold;"><ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_c8b3515445544fcca2b8f629f6a09ad6" contextRef="c20200801to20200801">400 3351</ix:nonNumeric></span>
          <div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
            </div>

          </div>

        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0);">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd678c307529540799a58c6e36e8b06fc">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_e70e24064dad4c969cea32c5057fcec9" contextRef="c20200801to20200801" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze213d7bd90f6496db38033765dd75164">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_dfee4791cba648db9af69d55f56df311" contextRef="c20200801to20200801" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3fab908f827c47d5b424fddc2b79f565">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_8cf63b55f1e044ac8fd66a7531b7c144" contextRef="c20200801to20200801" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f0184f52a78442190069156c2d2ce35">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_80766a5854d7422699d5b45865c79d95" contextRef="c20200801to20200801" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z905b5a1bf58e4630bb71a780e64d8f33">


  <tr>

    <td style="width: 1.01%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Title of each class</div>
            </td>

    <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 31%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Trading Symbol(s)</div>
            </td>

    <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 1.01%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c86e598c942f482f9b8b835a60e1dbdb" contextRef="c20200801to20200801">Common Shares, par value $0.000017727 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 31%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_d268b0fa9077422d83103432b9e305b6" contextRef="c20200801to20200801">MYOV</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_0d9183cd34854e5da76a0e61dc3a3a6b" contextRef="c20200801to20200801" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0);">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
          Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0);">Emerging growth company&#160;&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_2d289fdca3ea4afcb1d4d1f933c4c669" contextRef="c20200801to20200801" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
          new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69676a34c2e54db98b6ff0882ff17564">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Entry into a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Market Access Services Agreement</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On August 1, 2020, Myovant Sciences GmbH (&#8220;<span style="font-weight: bold;">MSG</span>&#8221;), a wholly-owned subsidiary of Myovant Sciences Ltd. (&#8220;<span style="font-weight: bold;">Myovant</span>&#8221;), entered into a Market Access Services Agreement (the &#8220;<span style="font-weight: bold;">Market Access Services Agreement</span>&#8221;) with Sunovion Pharmaceuticals Inc. (&#8220;<span style="font-weight: bold;">Sunovion</span>&#8221;),





        a subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (&#8220;<span style="font-weight: bold;">Sumitomo Dainippon</span>&#8221;). Sumitomo Dainippon beneficially owns a majority of Myovant&#8217;s outstanding shares through its sole ownership of Sumitovant Biopharma
        Ltd., Myovant&#8217;s majority shareholder (&#8220;<span style="font-weight: bold;">Sumitovant</span>&#8221;).</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Market Access Services Agreement, among other things, Sunovion has agreed to provide to MSG certain market access services with respect
        to the distribution and sale of relugolix monotherapy (relugolix 120 mg) (&#8220;<span style="font-weight: bold;">Prostate Cancer Product</span>&#8221;) and relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) (&#8220;<span style="font-weight: bold;">Women&#8217;s Health Product</span>,&#8221; and collectively with Prostate Cancer Product, the &#8220;<span style="font-weight: bold;">Products</span>&#8221;, and each a &#8220;<span style="font-weight: bold;">Product</span>&#8221; ), including, among
        other things: (i) adding the Products to Sunovion&#8217;s agreements with its third party logistics providers; (ii) adding the Women&#8217;s Health Product to certain of Sunovion&#8217;s contracts with wholesalers, group purchasing organizations and integrated
        delivery networks and negotiating rates for the Products with certain market access customers; (iii) providing order-to-cash services; (iv) providing certain employees to provide market access account director services; (v) performing activities
        required in connection with supporting and maintaining contracts between Myovant and market access customers for the coverage, purchase, or dispensing of the Products; (vi) managing the validation, processing and payment of rebates, chargebacks,
        and certain administrative, distribution and service fees related to the Products; (vii) providing MSG with price reporting metrics and other information required to allow Myovant to comply with applicable government price reporting requirements;
        (viii) coordinating with MSG and any applicable wholesalers and distributors to address any recalls, investigations, or product holds; (ix) configuring, or causing to be configured, the appropriate software systems to enable Sunovion to perform its
        obligations under the Market Access Services Agreement; and (x) providing training and certain other ancillary support services to facilitate the foregoing.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">MSG, in turn, appointed Sunovion as the exclusive distributor of the Women&#8217;s Health Product and a non-exclusive distributor of the Prostate Cancer
        Product, each in the United States, including all of its territories and possessions.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In order to facilitate Sunovion&#8217;s provision of these services, MSG agreed, among other things, to: (i) grant Sunovion a non-exclusive license under all
        intellectual property owned or controlled by MSG, solely for Sunovion&#8217;s use in connection with its performance of the contemplated services; (ii) provide Sunovion periodic reports of sales projections and estimated volume requirements, as well as
        such other information as Sunovion reasonably requests or may need to perform the services; (iii) comply with the provisions of any agreements between Sunovion and third parties pursuant to which the Products will be distributed or sold; (iv)
        cooperate with certain investigations related to orders and audits of MSG&#8217;s quality systems solely relate, as reasonably determined by Myovant, to Sunovion&#8217;s performance of certain regulatory services, at Sunovion&#8217;s costs; and (v) promptly notify
        Sunovion in the event relugolix is recalled.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As consideration for the services, MSG will pay Sunovion an agreed-upon monthly service charge for each of the first two years of the Market Access
        Services Agreement term and any agreed regulatory and training service charges. After the second year of the Market Access Services Agreement term, the monthly service charges will be determined by the parties. In addition, MSG also agreed to (x)
        reimburse Sunovion for any pass-through expenses it incurs while providing the services, and (y) establish an escrow fund for use by Sunovion when managing any rebates, chargebacks and similar fees.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Market Access Services Agreement also contains customary representations and warranties by the parties and customary provisions related to
        confidentiality, indemnification and insurance. The initial term of the Market Access Services Agreement is three years. Thereafter, the term will be automatically extended for one year periods, unless either party provides notice of its intent not
        to renew the Market Access Services Agreement at least nine (9) months prior to the expiration of the applicable term. Either party may also terminate the Market Access Services Agreement prior to the end of its term in the event of an uncured
        material breach by the other party, if there are certain changes of law, or if such other party becomes insolvent or undergoes a change of control. MSG may also terminate the Market Access Services Agreement with respect to one or both Products if
        Sunovion fails to satisfy certain market access milestones or for convenience upon payment of a break-up fee.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Market Access Services Agreement does not purport to be complete and is qualified in its entirety by reference to the
        complete text of the Market Access Services Agreement, which will be filed with Myovant&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2020.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Commitment Letter</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On August 5, 2020, Myovant obtained a debt commitment letter (the &#8220;<span style="font-weight: bold;">Commitment Letter</span>&#8221;) from Sumitomo Dainippon,
        pursuant to which, subject to the terms and conditions set forth therein, the Sumitomo Dainippon has committed to provide $200.0 million in unsecured revolving commitments (the &#8220;<span style="font-weight: bold;">New Credit Facility</span>&#8221;), the
        proceeds of which, may be used for business operating expenditures of Myovant and its subsidiaries. The commitments are in addition to the commitments made available to Myovant and its subsidiaries by Sumitomo Dainippon under the existing loan
        facility among Sumitomo Dainippon, Myovant and MSG dated as of December 27, 2019 (the &#8220;<span style="font-weight: bold;">Existing Credit Facility</span>&#8221;). Sumitomo Dainippon owns, indirectly, a majority of the outstanding voting shares of Myovant.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The New Credit Facility shall mature on the fifth anniversary of the closing of the New Credit Facility. Sumitomo Dainippon will have the discretion to
        require certain prepayments as Sumitomo Dainippon may request and/or to not allow Myovant to draw down any remaining funds under the New Credit Facility, upon the occurrence of certain material business development transactions. In addition, as a
        condition to the New Credit Facility, Myovant shall be required to enter into an information sharing agreement with Sumitovant which will be on terms to be agreed between Myovant and Sumitovant. The terms and conditions of the New Credit Facility
        shall otherwise be substantially identical to the terms of the Existing Credit Facility, including with respect to the interest rate margins, except as otherwise agreed between Myovant and Sumitomo Dainippon.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing summary of the Commitment Letter and the transactions contemplated thereby does not purport to be complete and is subject to, and
        qualified in its entirety by, the full text of the Commitment Letter, a copy of which will be filed with the SEC with Myovant&#8217;s Form 10-Q for the quarter ending September 30, 2020.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
          its behalf by the undersigned hereunto duly authorized.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zacecb6267da9486d82ee7f78d4e5edbc">


  <tr>

    <td style="width: 45.39%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 5.4%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Myovant Sciences Ltd.</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 45.39%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 5.4%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td colspan="2" rowspan="1" style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.39%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Date: August 5, 2020</div>
            </td>

    <td style="width: 5.4%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">By:</div>
            </td>

    <td style="border-bottom: 1px solid #000000; vertical-align: top; width: 25%; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">/s/ Matthew Lang</div>
            </td>

    <td style="width: 25%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45.39%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 5.4%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Name: Matthew Lang</div>
            </td>

  </tr>

  <tr>

    <td style="width: 45.39%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 5.4%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Title: General Counsel and Corporate Secretary</div>
            </td>

  </tr>


</table>
      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      </div>

    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "brhc10014092_8k.htm", "description": "8-K", "secsgml_size_bytes": 39286}]
{"company-data": {"conformed-name": "Myovant Sciences Ltd.", "cik": "0001679082", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "CA", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37929", "film-number": "201075854"}, "business-address": {"street1": "SUITE 1, 3RD FLOOR", "street2": "11-12 ST. JAMES SQUARE", "city": "LONDON", "state": "X0", "zip": "SW1Y 4LB", "phone": "44 207-400-3351"}, "mail-address": {"street1": "SUITE 1, 3RD FLOOR", "street2": "11-12 ST. JAMES SQUARE", "city": "LONDON", "state": "X0", "zip": "SW1Y 4LB"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 1, 2020
Myovant Sciences Ltd.
(Exact name of registrant as specified in its charter)
Bermuda
001-37929
98-1343578
(State or other jurisdiction of incorporation)
(Commission File No.)
(I.R.S. Employer Identification No.)
Suite 1, 3rd Floor
11-12 St. James's Square
London
SW1Y 4LB
United Kingdom
Not Applicable
(Address of principal executive office)
(Zip Code)
Registrant's telephone number, including area code:
+
44
207
400 3351
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, par value $0.000017727 per share
MYOV
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
          Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
          new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
Item 1.01
Entry into a Material Definitive Agreement.
Market Access Services Agreement
On August 1, 2020, Myovant Sciences GmbH ("
MSG
"), a wholly-owned subsidiary of Myovant Sciences Ltd. ("
Myovant
"), entered into a Market Access Services Agreement (the "
Market Access Services Agreement
") with Sunovion Pharmaceuticals Inc. ("
Sunovion
"),

        a subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("
Sumitomo Dainippon
"). Sumitomo Dainippon beneficially owns a majority of Myovant's outstanding shares through its sole ownership of Sumitovant Biopharma
        Ltd., Myovant's majority shareholder ("
Sumitovant
").
Pursuant to the Market Access Services Agreement, among other things, Sunovion has agreed to provide to MSG certain market access services with respect
        to the distribution and sale of relugolix monotherapy (relugolix 120 mg) ("
Prostate Cancer Product
") and relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) ("
Women's Health Product
," and collectively with Prostate Cancer Product, the "
Products
", and each a "
Product
" ), including, among
        other things: (i) adding the Products to Sunovion's agreements with its third party logistics providers; (ii) adding the Women's Health Product to certain of Sunovion's contracts with wholesalers, group purchasing organizations and integrated
        delivery networks and negotiating rates for the Products with certain market access customers; (iii) providing order-to-cash services; (iv) providing certain employees to provide market access account director services; (v) performing activities
        required in connection with supporting and maintaining contracts between Myovant and market access customers for the coverage, purchase, or dispensing of the Products; (vi) managing the validation, processing and payment of rebates, chargebacks,
        and certain administrative, distribution and service fees related to the Products; (vii) providing MSG with price reporting metrics and other information required to allow Myovant to comply with applicable government price reporting requirements;
        (viii) coordinating with MSG and any applicable wholesalers and distributors to address any recalls, investigations, or product holds; (ix) configuring, or causing to be configured, the appropriate software systems to enable Sunovion to perform its
        obligations under the Market Access Services Agreement; and (x) providing training and certain other ancillary support services to facilitate the foregoing.
MSG, in turn, appointed Sunovion as the exclusive distributor of the Women's Health Product and a non-exclusive distributor of the Prostate Cancer
        Product, each in the United States, including all of its territories and possessions.
In order to facilitate Sunovion's provision of these services, MSG agreed, among other things, to: (i) grant Sunovion a non-exclusive license under all
        intellectual property owned or controlled by MSG, solely for Sunovion's use in connection with its performance of the contemplated services; (ii) provide Sunovion periodic reports of sales projections and estimated volume requirements, as well as
        such other information as Sunovion reasonably requests or may need to perform the services; (iii) comply with the provisions of any agreements between Sunovion and third parties pursuant to which the Products will be distributed or sold; (iv)
        cooperate with certain investigations related to orders and audits of MSG's quality systems solely relate, as reasonably determined by Myovant, to Sunovion's performance of certain regulatory services, at Sunovion's costs; and (v) promptly notify
        Sunovion in the event relugolix is recalled.
As consideration for the services, MSG will pay Sunovion an agreed-upon monthly service charge for each of the first two years of the Market Access
        Services Agreement term and any agreed regulatory and training service charges. After the second year of the Market Access Services Agreement term, the monthly service charges will be determined by the parties. In addition, MSG also agreed to (x)
        reimburse Sunovion for any pass-through expenses it incurs while providing the services, and (y) establish an escrow fund for use by Sunovion when managing any rebates, chargebacks and similar fees.
The Market Access Services Agreement also contains customary representations and warranties by the parties and customary provisions related to
        confidentiality, indemnification and insurance. The initial term of the Market Access Services Agreement is three years. Thereafter, the term will be automatically extended for one year periods, unless either party provides notice of its intent not
        to renew the Market Access Services Agreement at least nine (9) months prior to the expiration of the applicable term. Either party may also terminate the Market Access Services Agreement prior to the end of its term in the event of an uncured
        material breach by the other party, if there are certain changes of law, or if such other party becomes insolvent or undergoes a change of control. MSG may also terminate the Market Access Services Agreement with respect to one or both Products if
        Sunovion fails to satisfy certain market access milestones or for convenience upon payment of a break-up fee.
The foregoing description of the Market Access Services Agreement does not purport to be complete and is qualified in its entirety by reference to the
        complete text of the Market Access Services Agreement, which will be filed with Myovant's Quarterly Report on Form 10-Q for the quarter ending September 30, 2020.
Commitment Letter
On August 5, 2020, Myovant obtained a debt commitment letter (the "
Commitment Letter
") from Sumitomo Dainippon,
        pursuant to which, subject to the terms and conditions set forth therein, the Sumitomo Dainippon has committed to provide $200.0 million in unsecured revolving commitments (the "
New Credit Facility
"), the
        proceeds of which, may be used for business operating expenditures of Myovant and its subsidiaries. The commitments are in addition to the commitments made available to Myovant and its subsidiaries by Sumitomo Dainippon under the existing loan
        facility among Sumitomo Dainippon, Myovant and MSG dated as of December 27, 2019 (the "
Existing Credit Facility
"). Sumitomo Dainippon owns, indirectly, a majority of the outstanding voting shares of Myovant.
The New Credit Facility shall mature on the fifth anniversary of the closing of the New Credit Facility. Sumitomo Dainippon will have the discretion to
        require certain prepayments as Sumitomo Dainippon may request and/or to not allow Myovant to draw down any remaining funds under the New Credit Facility, upon the occurrence of certain material business development transactions. In addition, as a
        condition to the New Credit Facility, Myovant shall be required to enter into an information sharing agreement with Sumitovant which will be on terms to be agreed between Myovant and Sumitovant. The terms and conditions of the New Credit Facility
        shall otherwise be substantially identical to the terms of the Existing Credit Facility, including with respect to the interest rate margins, except as otherwise agreed between Myovant and Sumitomo Dainippon.
The foregoing summary of the Commitment Letter and the transactions contemplated thereby does not purport to be complete and is subject to, and
        qualified in its entirety by, the full text of the Commitment Letter, a copy of which will be filed with the SEC with Myovant's Form 10-Q for the quarter ending September 30, 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
          its behalf by the undersigned hereunto duly authorized.
Myovant Sciences Ltd.
Date: August 5, 2020
By:
/s/ Matthew Lang
Name: Matthew Lang
Title: General Counsel and Corporate Secretary